Mutations in MEK and ERK are less studied but have been noted in developmental disorders and in both naturally occurring neoplasms and in response to BRaf inhibitors as a mechanism for resistance when treating cancers such as melanoma [219,220,221,222]. The gene discussed is BRAF; the disease is cancer.